Industry News

• Talon' product candidate Marqibo(R) to be assessed by Oncologic Drug Advisory Committee  Talon Therapeutics announced Marqibo® (vincristine sulfate liposomes injection) is scheduled to be assessed by ODAC March 21, 2012. Talon's NDA for Marqibo was accepted for filing by the FDA and is being reviewed under Accelerated Approval of New Drugs for Serious or Life Threatening Illnesses.
  February 03, 2012  
• Apricus Biosciences announces acquisition of NitroMist(TM) rights outside North America  Apricus announced an agreement with NovaDel Pharma for the sale and license of rights in territories outside of the U.S., Canada and Mexico to NovaDel's NitroMist®, an FDA-approved nitrate vasodilator indicated for acute relief of an attack or chest pain due to coronary artery disease.
  February 03, 2012  
• Transgenomic announces $22.0 million private placement   Transgenomic announced agreements with institutional and other accredited investors to raise $22.0 million in a private placement financing which includes an aggregate of $3.0 million in convertible notes issued in December to entities associated with Third Security, LLC.
  February 03, 2012  
• Gene regulator in brain's executive hub tracked across lifespan  For the first time, NIH scientists have tracked the activity, across the lifespan, of an environmentally responsive regulatory mechanism that turns genes on and off in the brain's executive hub.
  February 03, 2012  
• Depomed announces FDA approval of Merck's JANUMET(R) XR that accesses Depomed patents  Depomed announced that Merck's FDA approval of JANUMET® XR extended-release tablets, a new treatment for type 2 diabetes that combines sitagliptin, the active component of JANUVIA®. Depomed has provided Merck a license to patents directed to metformin extended release technology for JANUMET® XR.
  February 03, 2012  
• Threshold Pharmaceuticals and Merck KGaA announce global agreement  Threshold Pharma announced a global agreement with Merck KGaA to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug. TH-302 is currently being investigated in a global Phase 3 clinical trial in patients with soft tissue sarcoma.
  February 03, 2012  
• Medicago announces investment in Quebec City pilot production facility  Medicago announced it plans to invest $4 million to enhance the capacity of the pilot production facility located in Quebec City. The Company expects this investment to accelerate preclinical and clinical development timelines of future product candidates.
  February 03, 2012  
• Cabozantinib shows encouraging activity in heavily pretreated patients  Exelixis reported preliminary data from a cohort of heavily pretreated patients with metastatic refractory renal cell carcinoma participating in an ongoing phase 1b trial of cabozantinib. Tumor regression was observed in 19 of 21 patients (90%) with ¡Ý1 post-baseline assessment.
  February 03, 2012  
• Abiomed reports record revenue and earnings for third quarter  Abiomed reported third quarter fiscal 2012 revenue of $32.2 million, up 18% compared to revenue of $27.2 million in the same 2011 period, and GAAP net income of $2.9 million versus a GAAP net loss of $0.8 million in the prior year.
  February 03, 2012  
• Acorda presents preclinical data showing Dalfampridine improves motor functions  Acorda presented data showing that treatment with dalfampridine improved motor function in a preclinical model of stroke, with treatment initiated at least four weeks following the ischemic event. Dalfampridine is the active chemical ingredient in AMPYRA® (dalfampridine) Extended Release Tablets.
  February 03, 2012  

   (next 10 articles)